Special Issue

Interferons 2015

Message from the Guest Editor

Dear Colleagues The journal *Pharmaceuticals* will be publishing a Special Issue covering the topic, "Interferons", and I cordially invite you to contribute an article to this volume. Since their discovery over 50 years ago, interferons have impacted cancer research, autoimmunity, and host responses to infection. Also, a huge commercial market has developed for interferons because they became critical for treating hepatitis B and C. However, the use of interferons is changing. This Special Issue will highlight recent developments in the clinical use of these drugs (including Type I, II, and III interferons). In addition, we welcome the presentation and discussion of new preclinical models for interferons in order to offer participants a vision into the future of interferons in the clinic.

Guest Editor

Dr. Howard A. Young

Principal Investigator & Deputy Lab Chief, Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Bldg. 560/31-23, Chandler Street, Frederick, MD 21702-1201, USA

Deadline for manuscript submissions

closed (30 June 2015)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/3846

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

